Rapid Selection, Sequencing, and Production of Antibodies from Antigen-Specific Plasma Cells Recovered by FACS
Introduction
The Recombinant Antibody Production Core (RAPC) is a Texas resource that provides research and clinical faculty with antibody services for research, diagnostic, or therapeutic purposes. Our pipeline can generate custom human or mouse antibodies to a diverse variety of antigenic targets, including post-translational modifications.
Methods
Our workflow produces sequence identified, recombinant antibodies that can be engineered into single-chain fragments. The RAPC can clone antibodies from human patients by isolating single B cells from patient tissue or tumor samples. A bioinformatic team can also reconstruct, synthesize, and produce recombinant human antibodies derived from scRNA-seq datasets. By the recombinant nature of our antibodies, engineering efforts are streamlined allowing placement of fluorescent proteins, affinity tags, and other augmentation. Functionality testing capabilities are available for candidate human antibody therapeutics, as well as a cell-based antigen surface display system for hit validation. Scaled production of lead candidates is supported in-house.
Results
The RAPC pipeline has successfully produced, validated, and delivered recombinant monoclonal antibodies against a variety of antigenic targets from a diverse array of projects: pathogens, post-translational modifications, and therapeutic targets. We also have resurrected antibodies from human patient scRNA seq datasets and developed screening tools for hit confirmation and antigen identification of those antibodies.
Conclusion
RAPC offers holistic recombinant antibody services to support virtually any imaginable application.